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group), women prefer a posteriori an outpatient therapy
(88.6% in the group outpatient, 53.8% in the other
group), particularly because it is more restful (P 
0.001). CONCLUSION: If women prefer a posteriori an
outpatient therapy, this mode of care decreases the
amount of mobilized medical and social resources.
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COST OF TREATING HISPANIC PATIENTS 
WITH AIDS IN US HOSPITALS
O’Brien J, Pierce D, Jackson-Kelley H, Caro J
Caro Research, Concord, MA, USA
Hispanics have been reported to have one of the highest
rates of AIDS in the United States. OBJECTIVE: To ex-
amine the hospital costs and disposition status of Hispan-
ics with AIDS. METHODS: Inpatient cost estimates, ad-
justed for medical inflation and cost-to-charge ratios,
were developed using data from all-payer 1996 discharge
databases from California, Florida and Massachusetts,
supplemented with fee schedules. Log transformation
was used to address highly skewed distributions. Adults
(age 17 years) were dichotomized into Hispanic/non-
Hispanic groups. A hierarchical methodology using ICD9
and ID codes was developed to identify patient-level
data. Length-of-stay (LOS), disposition, emergency room
(ER), special care unit (SCU) and admission rates for
AIDS data were also examined. Hospital costs (i.e., ac-
commodation, ancillary, physician) are reported in 1998
US$. RESULTS: Of the 39,110 AIDS discharges, 6649
(17%) were coded as Hispanic. On average, Hispanics
were admitted for AIDS-related care 1.7 times during the
year versus 1.8 times for non-Hispanics. A difference of
0.4 days in LOS was noted between groups (Hispanics 
8.5; non-Hispanic  8.1); however, a higher mean per
diem cost of $1874 (difference  $117) was noted in the
non-Hispanic group. Thus, the difference in the overall
mean cost of a hospital stay, albeit slightly higher for
Hispanics ($14,101 vs $14,012), was small. Admission
via ER was 55% in Hispanics; 54% in non-Hispanics. Of
the 10.4% Hispanics and 9.1% non-Hispanics in SCUs,
SCU time accounted for 50% and 52% of the stay in each
group, respectively. Of those discharged alive, 2.6% more
of the non-Hispanics were referred for formal health care
services. CONCLUSIONS: Although some differences ex-
ist, the results do not appear to constitute a substantial
differential economic consequence between the groups.
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There are few analyses on rational drug prescription in
Turkey. The main social security systems which are
Emekli Sandigi and Bag-Kur have to reimburse and the
cost is very high. Due to the reimbursement of these irra-
tional prescriptions the social security systems (Emekli
Sandigi, Bag-Kur, Sosyal Sigortalar) have reached the
point of financial crisis and the systems need reorganiz-
ing. OBJECTIVE: Our aim was to conduct a preliminary
study to be able to establish the effects of prescribing
habits on the profile of antibiotic use for the treatment of
respiratory diseases in outpatients and its economic out-
come. METHODS: For this purpose 2278 randomized
prescriptions from January 1998 to September 1999
were collected from Emekli Sandigi and Bag-Kur. The
medical information including the length of time the
medications were extracted. RESULTS: The analysis on
the antibiotics prescribed revealed that of the total 6824
medicines 572 were antibiotics (8.4%). While sulbactam-
ampicillin was the widely prescribed antibiotic (20%),
azithromycin was the least (3%). The average total cost
of antibiotic treatment was $10.46 (range $1.27–$26.56)
per patient. CONCLUSIONS: Taking the results of this
pilot study into consideration, a master study for Turkey
is planned which will include cost-effectiveness analyses
for the empiric management of polymicrobial infections.
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Azithromycin IV was recently approved in Canada for
the treatment of community-acquired pneumonia (CAP)
requiring initial hospitalization. According to current
guidelines, a second or third generation cephalosporin 
a macrolide or an extended-spectrum fluoroquinolone is
preferred for first-line therapy. Azithromycin is well tol-
erated, reducing the potential for costly adverse events
and has a once daily dosing frequency, minimizing drug
preparation and administration costs. OBJECTIVES: To
compare the costs and outcomes of a 10-day course of
azithromycin IV/PO versus cefuroxime IV/PO  erythro-
mycin IV/PO. METHODS: The analysis was conducted
from the hospital perspective and considered 2 days of
intravenous followed by 8 days of oral therapy for a 10-
day course. A cost-minimization approach was used since
clinical trial results suggest similar efficacy and tolerabil-
ity between the comparators. The weighted cost of ce-
furoxime  erythromycin therapy was based on a clinical
trial where 52% of patients received cefuroxime alone
and 48% of patients received cefuroxime  erythromy-
cin for suspected atypical pathogens. The analysis in-
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cluded drug acquisition, supply and labour costs (in 1998
Canadian dollars). RESULTS: Two days of IV therapy
cost $57.48, $78.51 and $82.52, for azithromycin, eryth-
romycin, and cefuroxime, respectively. The total cost of a
10-day course of therapy was $136.36 for azithromycin
and $165.58 for cefuroxime  erythromycin ($126.36
for cefuroxime alone and $208.07 for cefuroxime 
erythromycin). Approximately 280 CAP patients were
seen at our institution in 1996, translating into potential
cost savings of $8,182 per year with azithromycin. CON-
CLUSION: Azithromycin IV/PO is a cost-effective alter-
native for in-patient treatment of CAP.
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OBJECTIVE: This study outlines the management strat-
egy used to treat ribavirin-induced hemolytic anemia
(RIHA) when used in combination therapy in the treat-
ment of chronic hepatitis C (CHC). It also estimates the
direct cost of treating RIHA per treatment course.
METHODS: A systematic review of the literature (1991–
1999) was conducted to abstract information on the fre-
quency and management of RIHA in the treatment of
CHC. Costs were obtained from a large private health in-
surance database from the state of Washington, and from
Drug Topics Red Book. Decision analytic techniques
were used to develop a model (base case) that estimated
the cost of RIHA. Additionally, several one-way sensitiv-
ity analyses, best and worst cases, and two additional
clinical scenarios were simulated with the model. RE-
SULTS: RIHA occurs in approximately 8% of those
treated for CHC. Standard of care dictates management
by dosage reduction or discontinuation of the ribavirin
component of therapy. The decrease in effectiveness of
therapy, as a result of this reduction/discontinuation, has
not been studied. We estimate the direct cost of treating
RIHA at $170 per patient per 48-week treatment course.
The cost ranges from $68 to $692 in the best and worst
case scenarios, respectively. CONCLUSIONS: RIHA is
an anticipated side effect of therapy for CHC. Manage-
ment of RIHA is simple and effective, however its impact
on overall treatment effectiveness is not known. The di-
rect cost of treating RIHA is low, although the likely de-
crease in effectiveness may increase indirect costs over
time, and deserves further study.
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Pneumonia was the third leading admitting diagnosis at a
large tertiary care hospital costing $12,653 per admis-
sion. The American Thoracic Society recommends the
use of a -lactam with or without macrolide as the pre-
ferred antimicrobial regimen for patients with CAP ad-
mitted to a non-ICU. OBJECTIVE: The objective of this
evaluation was to compare ceftriaxone alone (regimen 1)
versus ceftriaxone plus macrolide (regimen 2) using
length of stay, antibiotic costs, and total hospital charges
from a hospital perspective. METHODS: The data were
collected prospectively during December 1998 and May
1999. Fine et al 1998 defined risk scores for CAP and
classified them into 5 categories: 1 (low risk) through 5
(high risk). Most of our patient population belonged to
risk class 2. We compared 26 patients diagnosed with
CAP and stratified into risk class 2. Thirteen patients re-
ceived regimen 1 and 13 patients received regimen 2. RE-
SULTS: We found statistically significant differences in
hospital length of stay, antibiotic costs, and total hospital
charges. Patients who received ceftriaxone alone had
shorter lengths of stay (2.7  1.9 days vs. 5.6  3.9 days,
P  0.028), lower antibiotic costs ($93.02  $58.79 vs.
$169.11  $108.81, P  0.036), and lower total hospi-
tal charges per patient ($2,362.41  $1,442.18 vs.
$4,431.42  $3,108.92, P  0.040) than patients who
received ceftriaxone plus macrolide. CONCLUSION:
Ceftriaxone alone may be sufficient in the treatment of
hospitalized CAP patients who are classified in risk class 2.
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The seven-valent pneumococcal conjugate vaccine (PCV)
is the only vaccine to immunize children under two years
old against Streptococcus Pneumoniae, a leading cause of
meningitis, bacteremia, pneumonia, otitis media, and si-
nusitis. OBJECTIVE: The purpose of this analysis is to
assess the cost-effectiveness of PCV in Canada, the
United Kingdom, France, Germany, Italy, and Spain.
METHODS: A Markov cohort simulation model was
constructed to compare the health and economic out-
comes of children vaccinated with PCV versus unvacci-
nated. Estimated disease-specific incidence and mortality
